Literature DB >> 9804704

Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents.

I C Sun1, H K Wang, Y Kashiwada, J K Shen, L M Cosentino, C H Chen, L M Yang, K H Lee.   

Abstract

Succinyl and 3'-substituted glutaryl betulin derivatives showed stronger anti-HIV activity and higher therapeutic index (TI) values than their dihydrobetulin counterparts, with ratios of 1.2:1 to 15:1 (cf. 7 and 15, 9 and 17, 10 and 18, 11 and 19, and 12 and 20). For various 3'-substituted glutaryl compounds, the order of anti-HIV effects, from strong to weak inhibition, was 3',3'-dimethyl, 3'-methyl, 3'-ethyl-3'-methyl, followed by 3',3'-tetramethylene glutaryl derivatives (10 > 9 > 11 > 12, 18 > 17 > 19 > 20). The most potent compound, 10, has two 3',3'-dimethylglutaryl groups and displays significant anti-HIV potency with an EC50 value of 0.000 66 microM and a TI of 21 515. Results for compounds (22 and 23) without a C-3 acyl group confirmed the importance of the C-3 acyl group to the anti-HIV effect. With 3',3'-tetramethylene glutaryl derivatives, triacyl 29 showed stronger inhibition than diacyl 12; in contrast, 3',3'-dimethylglutaryl compounds displayed opposite results. 3-Keto compounds (35 and 36) and 2,3-dihydro compounds (39 and 40) had EC50 values in the range of 4.3-10.0 microM, suggesting that A ring modification led to decreased potency. The reduced activity of amide (33 and 34), ester (41), and oxime (42) analogues suggested that the orientation and linkage of the C-3 acyl side chain play crucial roles in the potent anti-HIV activity. Finally, replacing the C-28 acyl group with a bulky non-carboxylic group produced a less potent compound (44). In the study of mechanism of action, our results indicated that fusion is not the primary target for the anti-HIV activity of 10. It appears to inhibit HIV replication at a late stage of the viral life cycle, i.e., after viral protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804704     DOI: 10.1021/jm980391g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Understanding the structure-activity relationship of betulinic acid derivatives as anti-HIV-1 agents by using 3D-QSAR and docking.

Authors:  Ping Lan; Wan-Na Chen; Zhi-Jian Huang; Ping-Hua Sun; Wei-Min Chen
Journal:  J Mol Model       Date:  2010-10-27       Impact factor: 1.810

2.  Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.

Authors:  Donglei Yu; Yojiro Sakurai; Chin-Ho Chen; Fang-Rong Chang; Li Huang; Yoshiki Kashiwada; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

3.  Study of the betulin molecule in a water environment; ab initio and molecular simulation calculations.

Authors:  Miroslav Pospíšil; Petr Kovář; Robert Vácha; Michal Svoboda
Journal:  J Mol Model       Date:  2011-05-03       Impact factor: 1.810

4.  Conjugates of betulin derivatives with AZT as potent anti-HIV agents.

Authors:  Juan Xiong; Yoshiki Kashiwada; Chin-Ho Chen; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee; Yoshihisa Takaishi
Journal:  Bioorg Med Chem       Date:  2010-07-07       Impact factor: 3.641

5.  Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.

Authors:  S L Holz-Smith; I C Sun; L Jin; T J Matthews; K H Lee; C H Chen
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  An Active Drimane-Type Lactone from Polygonum jucundum Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice Through TLR4-MAPKs Signaling Pathway.

Authors:  Yang Hu; Lijun Tao; Hui Tan; Mian Zhang; Kuniyoshi Shimizu; Fei Zhang; Chaofeng Zhang
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

7.  Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.

Authors:  Keduo Qian; Donglei Yu; Chin-Ho Chen; Li Huang; Susan L Morris-Natschke; Theodore J Nitz; Karl Salzwedel; Mary Reddick; Graham P Allaway; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

8.  Improving physical properties via C-H oxidation: chemical and enzymatic approaches.

Authors:  Quentin Michaudel; Guillaume Journot; Alicia Regueiro-Ren; Animesh Goswami; Zhiwei Guo; Thomas P Tully; Lufeng Zou; Raghunath O Ramabhadran; Kendall N Houk; Phil S Baran
Journal:  Angew Chem Int Ed Engl       Date:  2014-09-22       Impact factor: 15.336

9.  3,28-Diacet-oxy-29-bromo-betulin.

Authors:  Wei-Min Ding; Li-Jia Jing; Tao Yu; Yang Wang; Xiu-Feng Yan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-25

10.  The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.

Authors:  Albert T Nguyen; Christa L Feasley; Ken W Jackson; Theodore J Nitz; Karl Salzwedel; Gillian M Air; Michael Sakalian
Journal:  Retrovirology       Date:  2011-12-07       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.